[ad_1]
The vaccine committee in Germany updated the recommendation regarding the product developed by AstraZeneca in partnership with the University of Oxford, stating that the covid-19 immunizer should only be administered to people under 65 years of age.
To justify the new recommendation, the experts cited the lack of sufficient data for the older age groups.
“Currently, there is not enough data available to evaluate the effectiveness of the vaccine from the age of 65,” the committee said in the resolution made available by the German health ministry.
“The AstraZeneca vaccine, unlike the mRNA vaccines (Moderna and Pfizer), should only be offered to people between the ages of 18 and 64 at each stage,” he added.
EU vs AstraZeneca arms fight
Germany’s recommendation predates that of the European Medicines Agency, which is due to make a decision on approval of the AstraZeneca vaccine tomorrow. At the moment, the company faces a dispute with the European Union.
The EU had already purchased the immunizer in advance. In total, there are 400 million doses, worth 336 million euros.
The expectation was that 80 million of these doses would be delivered by the end of March. However, the Anglo-Swedish company said it could only supply 31 million doses in this period and anticipated a 50% cut in the second quarter.
Brussels does not accept AstraZeneca’s arguments and is considering restricting the export of covid-19 vaccines produced by companies based in the European Union. This question should be decided later this week.
Of the four laboratory units included in the contract as vaccine production plants for the European bloc, one is located in the city of Puurs, Belgium, another in Germany and the rest in the United Kingdom.
* With information from Reuters and RFI
[ad_2]
